Skip to main content
Two is better than one: combining IGF1R and MEK blockade as a promising novel treatment strategy against KRAS-mutant lung cancer.
Targeting MYCN in neuroblastoma by BET bromodomain inhibition.
Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers.